This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

GEORGE H. REICHLING, M.D; ALBERT M. KLIGMAN, M.D.

Arch Dermatol. 1961;83(6):980-983.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The aim of this study was to devise a way of minimizing the adverse side-reactions of long-term corticosteroid therapy. The working hypothesis upon which we founded our hope of success is based upon the principle that substances in the blood stream tend to concentrate at inflamed sites and become fixed there.^1-3 For example, trypan blue dye, when injected intravenously, will localize at a site of previously induced inflammation, staining the tissue deeply.¹

Conventionally, steroids are given in divided daily doses. Presumably, this provides sustained blood levels. But if steroids do concentrate and fix at sites of inflammation, there would be no necessity for sustained blood levels. Indeed, the peak levels might be more important. Therefore, we decided to give single doses every other day. By reducing the duration of high levels, it was thought that adverse side-effects might be minimized, without weakening the therapeutic effect. This method would . . . [Full Text PDF of this Article]

Author Affiliations
PHILADELPHIA

Footnotes
Submitted for publication Dec. 19, 1960.

This work was supported in part by Training Grant PHS-2G-62, National Institute of Health and Lederle Laboratories, Division of American Cyanamid Company.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?